Metformin, a biguanide, typically produces modest weight reduction through metabolic pathways, whilst Rybelsus, a GLP-1 receptor agonist, directly targets appetite regulation centres
Reprod BioMed Online (2013) 26(1):6878
Thus, whilst the CVOTs provide valuable and supportive evidence of a benefit of GLP-1 RAs on HF in people with type 2 diabetes, additional trials are required to fully understand the magnitude and nature of such a potential effect, including if it applies to both prevention and treatment of the condition
Some Ozempic users have often reported the slightly paradoxical side effect of weight gain, despite the medications inherent properties that often lead to weight loss
SELECT trial demonstrated 20% MACE reduction